London Stock ExchangeLondon Stock Exchange

REG - Intertek Group Plc - Acquisition

Refinitiv閱讀2分鐘
RNS Number : 7921F Intertek Group PLC 03 November 2025  

INTERTEK EXPANDS ATIC FOOTPRINT IN CENTRAL AMERICA WITH ACQUISITION OF LEADING COSTA RICAN TESTING BUSINESS SUPLILAB

•      Fast-growing Costa Rican economy is driving a strong demand for Risk-based Quality Assurance services in food safety and medical device testing sectors

•      Suplilab is a high-quality ATIC provider with a leading scale position and a track record of fast growth in high-margin sectors

•      Acquisition of Suplilab gives Intertek immediate access to attractive ATIC growth opportunities in Central America

More information is available here: https://www.intertek.com/investors/suplilab-video/

3 November 2025: Intertek Group plc ("Intertek" and "Group"), a leading Total Quality Assurance provider to industries worldwide, is pleased to announce that it has acquired Suplilab, a market-leading provider of food safety and medical devices testing services, based in San José, Costa Rica.

The Costa Rican economy is growing rapidly, creating a significant market for Risk-based Quality Assurance solutions that can cater to rising demand from consumers for safer and more sustainable food options, and the strong expansion of the country's medical devices market.

Suplilab is a high-quality business with industry-leading technical expertise in microbiology, water and chemistry testing and has established a market-leading position in the food and medical devices sectors based on a strong track record of rapid growth in these high-margin spaces. Suplilab employs 38 highly skilled colleagues and generated revenues of £3.1m in 2024.

The acquisition will enable Intertek to establish a leading position in Costa Rica's food and medical devices sectors, offering immediate access to a large customer base and a fast-growing ATIC market in Central America.

André Lacroix, Chief Executive Officer of Intertek, said: "The acquisition of Suplilab in Costa Rica is an exciting opportunity to enter into Central America's high-growth, high-margin food and medical devices spaces, deepening our industry-leading ATIC footprint in Latin America. We look forward to working with the Suplilab team to seize the exciting growth opportunities ahead."

-ENDS-

For further information please contact:

Denis Moreau, Investor Relations

Telephone: +44 (0) 20 7396 3415                    investor@intertek.com 

Jonathon Brill/James Styles, DGA

Telephone: +44 (0) 7836 622 683               intertek@dgagroup.com

About Intertek

Intertek is a leading Total Quality Assurance provider to industries worldwide.

Our network of more than 1,000 laboratories and offices in more than 100 countries, delivers innovative and bespoke Assurance, Testing, Inspection and Certification solutions for our customers' operations and supply chains. Intertek is a purpose-led company that brings Quality, Safety and Sustainability to Life.

Our Science-based Customer Excellence USP and the 24/7 mission critical Quality Assurance solutions we provide, ensure that our clients can operate with well-functioning supply chains in each of their operations.

Our Customer Promise is: Intertek Total Quality Assurance expertise, delivered consistently, with precision, pace and passion, enabling our customers to power ahead safely.

intertek.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.  END  ACQEANFFESFSFFA

登入或建立一個永久免費帳戶來閱讀此新聞